52
Participants
Start Date
September 30, 2013
Primary Completion Date
June 30, 2017
Study Completion Date
June 30, 2017
sipuleucel-T
Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
enzalutamide
Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
North Shore Hematology/Oncology Associates, P.C., East Setauket
Associated Medical Professionals of New York, PLLC, Syracuse
Thomas Jefferson University, Philadelphia
Johns Hopkins Medicine - Sidney Kimmel Comprehensive Cancer Center, Baltimore
Urology of Virginia, Virginia Beach
Raleigh Hematology Oncology Associates, D.B.A. Cancer Centers of North Carolina, Raleigh
Carolina Urologic Research Center, Myrtle Beach
H. Lee Moffitt Cancer and Research Center, Tampa
Urology Associates, PC, Nashville
Cleveland Clinic - Taussig Cancer Institute, Cleveland
Uro Partners/ RMD Clinical Research, Melrose Park
GU Research Network, Omaha
The Urology Center of Colorado, Denver
Urological Associates of Southern Arizona, P.C., Tucson
USC/Norris Comprehensive Cancer Center, Los Angeles
Virginia Mason Medical Center, Virginia Mason Hospital, Seattle
Northwest Medical Specialties, Rainier Physicians, Tacoma
Yale University School of Medicine, New Haven
Fort Wayne Medical Oncology and Hematology, Lutheran Hospital, Parkview Regional Medical Center, Fort Wayne
Lead Sponsor
Dendreon
INDUSTRY